comparemela.com

Latest Breaking News On - Cardiff oncology - Page 3 : comparemela.com

Cardiff Oncology (CRDF) Scheduled to Post Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF – Get Free Report) will be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Cardiff Oncology to post earnings of ($0.25) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Cardiff Oncology (NASDAQ:CRDF […]

California
United-states
Piper-sandler
Cardiff-oncology-company-profile
Cardiff-oncology-inc
Nasdaq
Cardiff-oncology
Get-free-report
Oncology-stock-down
Polo-like-kinase
Cardiff-oncology-daily
Nasdaq-crdf

Global PLK Targeted Therapies Market Opportunity & Clinical

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

RAS-mutated mCRC– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulti.

San-diego
California
United-states
American
James-levine
Kiki-patel
Mark-erlander
Nasdaq
American-association-for-cancer-research
Online-program
Gilmartin-group
Taft-communications

Adagrasib, Cetuximab May Benefit KRASG12c Colorectal Cancer Patients

Adagrasib, Cetuximab May Benefit KRASG12c Colorectal Cancer Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United-states
Texas
American
Redx-pharma
Daiichi-sankyo
Bristol-myers-squibb-medarex
Genentech-roche
Eli-lilly
Scott-kopetz
Navire-pharma
Astrazeneca-medimmune
Lutris-pharma

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Texas
United-states
Houston
San-diego
California
American
Daiichi-sankyo
Bristol-meyers-squibb
Redx-pharma
Eli-lilly
Navire-pharma
Genentech-roche

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.